iPrEx Study

iPrEx Study was a landmark clinical trial that investigated the efficacy of Pre-exposure prophylaxis (PrEP) in preventing HIV infection among high-risk individuals, particularly Men who have sex with men (MSM) and Transgender women. The study was conducted by a team of researchers from the University of California, San Francisco, in collaboration with the National Institutes of Health and the Bill and Melinda Gates Foundation. The trial involved participants from several countries, including Brazil, Ecuador, Peru, South Africa, Thailand, and the United States, and was supported by organizations such as the World Health Organization and the Joint United Nations Programme on HIV/AIDS.

Introduction

The iPrEx Study was designed to evaluate the safety and efficacy of daily oral Tenofovir disoproxil fumarate (TDF) and Emtricitabine (FTC) in preventing HIV infection among high-risk individuals. The study built upon previous research on Antiretroviral therapy and HIV prevention, including the work of scientists such as David Ho and Anthony Fauci. The trial was conducted in collaboration with several institutions, including the University of California, Los Angeles, Harvard University, and the London School of Hygiene and Tropical Medicine. The study's findings were published in the New England Journal of Medicine and presented at conferences such as the International AIDS Conference and the Conference on Retroviruses and Opportunistic Infections.

Background

The iPrEx Study was motivated by the need for effective HIV prevention strategies, particularly among high-risk populations such as Men who have sex with men and Sex workers. The study drew on the expertise of researchers from institutions such as the Centers for Disease Control and Prevention, the World Health Organization, and the National Institute of Allergy and Infectious Diseases. The trial was also informed by the work of activists and advocates, including ACT UP and the Global Network of People Living with HIV. The study's design and implementation were influenced by the principles of Evidence-based medicine and the guidelines of the National Institutes of Health and the Food and Drug Administration.

Methodology

The iPrEx Study was a randomized, double-blind, placebo-controlled trial that enrolled 2,499 participants from 11 sites in 6 countries, including Brazil, Ecuador, Peru, South Africa, Thailand, and the United States. The study was conducted in collaboration with several institutions, including the University of California, San Francisco, Harvard University, and the London School of Hygiene and Tropical Medicine. Participants were randomly assigned to receive either daily oral TDF/FTC or a placebo, and were followed for a median of 1.2 years. The study's methodology was influenced by the work of statisticians such as Ronald Fisher and Jerzy Neyman, and was designed to meet the standards of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.

Results

The iPrEx Study found that daily oral TDF/FTC reduced the risk of HIV infection by 44% among participants who received the active drug, compared to those who received the placebo. The study's results were significant, with a P-value of <0.001, and were published in the New England Journal of Medicine. The study's findings were also presented at conferences such as the International AIDS Conference and the Conference on Retroviruses and Opportunistic Infections, and were widely reported in the media, including The New York Times, The Lancet, and Science. The study's results have been cited by researchers such as Anthony Fauci and David Ho, and have influenced the development of HIV prevention guidelines by organizations such as the Centers for Disease Control and Prevention and the World Health Organization.

Impact

The iPrEx Study has had a significant impact on the field of HIV prevention, and has informed the development of guidelines and policies by organizations such as the Centers for Disease Control and Prevention, the World Health Organization, and the Joint United Nations Programme on HIV/AIDS. The study's findings have been cited by researchers such as Anthony Fauci and David Ho, and have influenced the work of activists and advocates, including ACT UP and the Global Network of People Living with HIV. The study's results have also been recognized by awards such as the National Medal of Science and the Lasker Award, and have been featured in publications such as The New York Times, The Lancet, and Science. The study's impact extends beyond the field of HIV prevention, and has contributed to the development of Evidence-based medicine and the principles of Public health. Category:HIV/AIDS research